Respiratory symptoms in a patient on anti-tumour necrosis factor therapy; beware the negative enzyme linked immuno-spot (ELISpot) in suspected mycobacterial disease.
Mangat
P
P
Kennedy Institute of Rheumatology Division, Imperial College London and Charing Cross Hospital, Imperial College Healthcare NHS Trust, UK. pamela.mangat@imperial.ac.uk
Taylor
P
P
Abraham
S
S
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003371:Cough / Q000209:etiology; D004417:Dyspnea / Q000209:etiology; D058501:Enzyme-Linked Immunospot Assay; D005221:Fatigue / Q000209:etiology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D055985:Latent Tuberculosis / Q000175:diagnosis*; D008875:Middle Aged; D009161:Mycobacterium / Q000145:classification / Q000302:isolation & purification*; D011237:Predictive Value of Tests; D014057:Tomography, X-Ray Computed; D014374:Tuberculin Test / Q000379:methods; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha